Bristol, Merck checkpoint inhibitors focus of FDA advisory committee meeting
An FDA advisory panel on Bristol Myers Squibb Opdivo and Merck Keytruda will examine if PD-L1 tumor expression should limit ...
FiercePharma7h
Ahead of adcomm, FDA challenges broad use of PD-1 drugs in stomach cancer patients
Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...
Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025
First signs of clinical benefit in adjuvant head and neck cancer reported at AACR 2024, paved the way for the start of Phase II part of randomized Phase I/II clinical trial in Q2 2024 – Median ...
The Pharma Letter14h
Two regulatory approvals for Astellas
In a news packed morning, Japanese drugmaker Astellas Pharma (TYO: 4503) today revealed two regulatory approvals.
From Iran to Icon: How Immigrant Maky Zanganeh Became a Self-Made Billionaire in the US
Maky Zanganeh, Co-CEO of Summit Therapeutics' owns 5% of the biopharmaceutical company and stock options. One of the 34 ...
How Iran Immigrant Maky Zanganeh Is Now A Self-Made Billionaire In US
Maky Zanganeh became a billionaire after shares of Summit Therapeutics, where she serves as co-CEO, soared following positive ...
Daily21h
Merck gets positive EU CHMP opinions for Keytruda regimens for patients with two types of Gynecologic cancers
Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency's ...